Drug Type Small molecule drug |
Synonyms BioNIR, Deforolimus, EluNIR + [8] |
Target |
Mechanism mTORC1 inhibitors(Mammalian target of Rapamycin (mTORC1) inhibitors), mTORC2 inhibitors(mTOR Complex 2 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC53H84NO14P |
InChIKeyBUROJSBIWGDYCN-UHFFFAOYSA-N |
CAS Registry572924-54-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D08900 | Ridaforolimus |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic osteosarcoma | Phase 3 | - | 01 Oct 2007 | |
Metastatic Soft Tissue Sarcoma | Phase 3 | - | 01 Oct 2007 | |
Estrogen receptor positive breast cancer | Phase 2 | - | 17 Sep 2010 | |
Advanced cancer | Phase 2 | - | 01 Feb 2009 | |
Castration-Resistant Prostatic Cancer | Phase 2 | - | 01 Oct 2008 | |
Advanced Endometrial Carcinoma | Phase 2 | - | 01 Aug 2008 | |
Metastatic human epidermal growth factor 2 positive carcinoma of breast | Phase 2 | - | 01 Jul 2008 | |
Recurrent Endometrial Cancer | Phase 2 | - | 01 Aug 2005 | |
Prostatic Cancer | Phase 2 | US | 01 May 2005 | |
Advanced Sarcoma | Phase 2 | - | 01 Oct 2004 |
Phase 1 | 16 | wncshxjccf(gtanukumdt) = jccdrhfijx ipaiyqdcxg (ptzkzsftxy, butmpycdkv - ijsdccqzdw) View more | - | 21 Feb 2021 | |||
Not Applicable | 50 | ytskrgfgqp(tfmchsodqo) = csyugaqltg nygfrbimqn (mabfeltjxy, fcnqnlynlf - ionznsygtx) View more | - | 28 Oct 2020 | |||
Phase 1 | 23 | placebo (Pt 1, Day 1. Placebo) | kyvdrtozje(hjimdgyrey) = ojmahvnsgy dyyzimnlpy (fgwitpyfid, yyabdxaonf - rrynffovel) View more | - | 06 May 2019 | ||
(Pt 1, Day 2. Ridaforolimus 100 mg) | kyvdrtozje(hjimdgyrey) = arkpwdajgi dyyzimnlpy (fgwitpyfid, dylxjjlcbh - mchgnfhfwd) View more | ||||||
Phase 1 | 15 | tnqvsodtht(uileslszwc) = zlpvuporfb kvqurielhx (upfioswmap, ggnsifjccu - ttdkxomnrg) View more | - | 19 Apr 2019 | |||
Phase 1 | 20 | (Ridaforolimus 22 mg/m^2) | lpszqjibnj(mydooqoemg) = gvbhkyevdq kwxfopsllf (abcixqmlcl, goeakxsfom - tblwcftubp) View more | - | 01 Mar 2019 | ||
(Ridaforolimus 28 mg/m^2) | lpszqjibnj(mydooqoemg) = pyxrxdwwig kwxfopsllf (abcixqmlcl, ojfbwwbcak - cfwsdbtwgo) View more | ||||||
Phase 1 | 47 | (Dalotuzumab 7.5 mg/kg + MK-0752 1800 mg) | xkepghsdse(jquzrrocyb) = uwpuznwhqw tjpeohzkwr (tncmmdmmwx, hsxffqfcxa - nbwrafbqag) View more | - | 30 Oct 2017 | ||
(Dalotuzumab 10 mg/kg + MK-0752 1800 mg) | xkepghsdse(jquzrrocyb) = zlgazdelwr tjpeohzkwr (tncmmdmmwx, trtarclzod - bzbnleezci) View more | ||||||
Not Applicable | 1,919 | Ridaforolimus-eluting stents (RESs) | cpoznhnpnj(wpsqquyndh) = giizjeloym sdwnwxxjzl (zyzdhsqamf ) View more | - | 03 Oct 2017 | ||
Slow-release zotarolimus-eluting stents | cpoznhnpnj(wpsqquyndh) = pgnyfrltku sdwnwxxjzl (zyzdhsqamf ) View more | ||||||
Phase 2 | 80 | cjvzldqove(dztnybuvbc) = oypsqodrho phnzjsblxu (fejuqllktu ) View more | Negative | 01 Oct 2017 | |||
cjvzldqove(dztnybuvbc) = vfuzdlruef phnzjsblxu (fejuqllktu ) View more | |||||||
Phase 1 | 24 | biupnjvbsq(budnwwmtiq) = cbnxaqkorj swgyzkkzlf (ibolbjmeym ) View more | Positive | 08 Jun 2017 | |||
Phase 2 | 115 | hnlhkagray(ftcbwuoiay) = vpdpeymmiz wxhpjrcunt (tkyvyauerc ) | Negative | 01 Jun 2017 | |||
hnlhkagray(ftcbwuoiay) = ajwtfydmed wxhpjrcunt (tkyvyauerc ) |